AFIB · Acutus Medical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $5.27M | $4.13M | $3.63M | - | $5.24M | $5.29M | $4.17M | - | $3.64M |
| Cost of Revenue | - | $4.89M | $4.47M | $3.65M | - | $8.60M | $8.06M | $6.79M | - | $6.95M |
| Gross Profit | - | $372.0K | ($343.0K) | ($30.0K) | - | ($3.36M) | ($2.77M) | ($3.26M) | - | ($3.31M) |
| R&D | - | $0 | $0 | $0 | - | $4.79M | $6.80M | $6.12M | - | $5.95M |
| SG&A | - | $2.32M | $2.23M | $3.34M | - | $7.43M | $9.28M | $9.56M | - | $9.68M |
| Total Operating Expenses | - | ($117.0K) | ($644.0K) | $545.0K | - | $17.15M | ($20.55M) | $14.69M | - | $24.11M |
| D&A | - | $100.0K | $100.0K | $86.0K | - | $1.00M | $1.20M | $1.30M | - | $1.50M |
| Operating Income | - | $489.0K | $301.0K | ($575.0K) | - | ($12.94M) | ($17.17M) | ($17.31M) | - | ($20.46M) |
| Interest Expense | - | $1.41M | $1.51M | $1.48M | - | $1.41M | $1.40M | $1.31M | - | $1.11M |
| Income Tax | - | - | - | $0 | - | $75.0K | $0 | $0 | - | $0 |
| Net Income | - | ($5.61M) | ($914.0K) | ($1.62M) | - | ($13.24M) | ($18.35M) | ($16.32M) | - | ($20.43M) |
| EPS - Basic | - | ($0.19) | ($0.03) | ($0.06) | - | ($0.45) | ($0.63) | ($0.57) | - | ($0.72) |
| EPS - Diluted | - | ($0.19) | ($0.03) | ($0.06) | - | ($0.45) | ($0.63) | ($0.57) | - | ($0.72) |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.02M | $12.60M | $13.33M | $18.46M | $19.17M | $24.10M | $23.05M | $22.74M | $25.58M | $28.00M |
| Accounts Receivable | $7.88M | $9.97M | $9.23M | $7.75M | $11.35M | $8.95M | $7.67M | $5.34M | $21.09M | $3.21M |
| Inventory | $1.79M | $4.19M | $5.21M | $5.89M | $4.28M | $15.73M | $15.67M | $14.94M | $13.33M | $14.60M |
| Accounts Payable | $1.28M | $1.71M | $1.68M | $3.17M | $2.76M | $4.75M | $5.49M | $5.57M | $4.72M | $4.64M |
| Current Assets | $25.58M | $27.16M | $28.46M | $34.40M | $46.25M | $72.64M | $87.30M | $101.79M | $117.87M | $93.89M |
| Total Assets | $28.65M | $32.17M | $35.47M | $41.67M | $53.96M | $84.73M | $100.30M | $116.00M | $133.44M | $114.63M |
| Current Liabilities | $12.44M | $14.66M | $12.38M | $9.87M | $18.94M | $14.77M | $18.22M | $17.11M | $19.87M | $18.32M |
| Long-term Debt | $25.56M | $25.27M | $25.13M | $32.80M | $32.65M | $34.76M | $34.63M | $34.53M | $34.43M | $34.31M |
| Total Liabilities | $40.24M | $42.47M | $40.28M | $45.69M | $54.84M | $53.02M | $56.55M | $55.53M | $58.42M | $56.85M |
| Stockholders' Equity | ($11.59M) | $31.71M | $43.74M | ($4.02M) | ($879.0K) | $31.71M | $43.74M | $60.47M | $75.02M | $57.78M |
| Retained Earnings | ($609.52M) | ($608.12M) | ($602.51M) | ($601.60M) | ($599.98M) | ($566.21M) | ($552.98M) | ($534.63M) | ($518.31M) | ($533.42M) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($16.93M) | - | - | - | ($16.52M) | - | - |
| Investing Cash Flow | - | - | - | $9.23M | - | - | - | $15.25M | - | - |
| Financing Cash Flow | - | - | - | ($42.0K) | - | - | - | ($213.0K) | - | - |
| CapEx | - | - | - | $105.0K | - | - | - | $232.0K | - | - |
| Free Cash Flow | - | - | - | ($17.03M) | - | - | - | ($16.75M) | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 7.1% | -8.3% | -0.8% | - | -64.1% | -52.4% | -78.2% | - | -90.8% |
| Operating margin | - | 9.3% | 7.3% | -15.9% | - | -247.0% | -324.7% | -415.0% | - | -561.5% |
| EBITDA margin | - | 11.2% | 9.7% | -13.5% | - | -227.9% | -302.0% | -383.9% | - | -520.3% |
| Net margin | - | -106.5% | -22.1% | -44.7% | - | -252.7% | -346.9% | -391.2% | - | -560.5% |
| Free cash flow margin | - | - | - | -469.9% | - | - | - | -401.6% | - | - |
| FCF / Net income | - | - | - | 10.51 | - | - | - | 1.03 | - | - |
| R&D / Revenue | - | 0.0% | 0.0% | 0.0% | - | 91.5% | 128.5% | 146.7% | - | 163.2% |
| SG&A / Revenue | - | 44.0% | 53.9% | 92.1% | - | 141.9% | 175.5% | 229.4% | - | 265.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -17.4% | -2.6% | -3.9% | - | -15.6% | -18.3% | -14.1% | - | -17.8% |
| Return on equity | - | -17.7% | -2.1% | 40.3% | - | -41.7% | -41.9% | -27.0% | - | -35.3% |
| Return on invested capital | - | - | - | -1.6% | - | -15.4% | -17.3% | -14.4% | - | -17.6% |
| Liquidity | ||||||||||
| Current ratio | 2.06 | 1.85 | 2.30 | 3.48 | 2.44 | 4.92 | 4.79 | 5.95 | 5.93 | 5.12 |
| Quick ratio | 1.91 | 1.57 | 1.88 | 2.89 | 2.22 | 3.85 | 3.93 | 5.08 | 5.26 | 4.33 |
| Cash ratio | 1.13 | 0.86 | 1.08 | 1.87 | 1.01 | 1.63 | 1.27 | 1.33 | 1.29 | 1.53 |
| Leverage | ||||||||||
| Debt / Equity | -2.21 | 0.80 | 0.57 | -8.16 | -37.15 | 1.10 | 0.79 | 0.57 | 0.46 | 0.59 |
| Debt / Assets | 0.89 | 0.79 | 0.71 | 0.79 | 0.61 | 0.41 | 0.35 | 0.30 | 0.26 | 0.30 |
| Debt / EBITDA | - | 42.90 | 62.67 | - | - | - | - | - | - | - |
| Interest coverage | - | 0.3x | 0.2x | -0.4x | - | -9.2x | -12.3x | -13.2x | - | -18.4x |
| Equity multiplier | -2.47 | 1.01 | 0.81 | -10.37 | -61.39 | 2.67 | 2.29 | 1.92 | 1.78 | 1.98 |
| Liabilities / Assets | 1.40 | 1.32 | 1.14 | 1.10 | 1.02 | 0.63 | 0.56 | 0.48 | 0.44 | 0.50 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.16 | 0.12 | 0.09 | - | 0.06 | 0.05 | 0.04 | - | 0.03 |
| Inventory turnover | - | 1.17 | 0.86 | 0.62 | - | 0.55 | 0.51 | 0.45 | - | 0.48 |
| Days sales outstanding | - | 691d | 817d | 780d | - | 624d | 529d | 467d | - | 322d |
| Days inventory outstanding | - | 313d | 426d | 588d | - | 668d | 709d | 803d | - | 766d |
| Days payable outstanding | - | 128d | 137d | 316d | - | 202d | 249d | 299d | - | 244d |
| Cash conversion cycle | - | 876d | 1105d | 1052d | - | 1090d | 990d | 971d | - | 845d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | 0.1x | 0.0x | - | - | 0.6x | 0.6x | 0.4x | - | 0.4x |
| P / S | - | 0.5x | 0.3x | 1.5x | - | 3.9x | 4.9x | 5.2x | - | 6.8x |
| EV / EBITDA | - | 25.8x | 32.1x | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 0.5% | -22.0% | -13.1% | - | 43.7% | 29.8% | 13.3% | - | -20.8% |
| Revenue CAGR (3y) | - | 4.6% | -4.3% | 31.8% | - | 100.9% | 93.1% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | 87.6% | 99.1% | - | -1.5% | 50.6% | 0.0% | - | 16.0% |
| Operating income growth (YoY) | - | - | - | 96.7% | - | 36.8% | - | 55.2% | - | 24.5% |
| Net income growth (YoY) | - | 57.6% | 95.0% | 90.1% | - | 35.2% | - | 59.2% | - | 28.4% |
| EPS growth (YoY) | - | 57.8% | 95.2% | 89.5% | - | 37.5% | - | 45.2% | - | 23.4% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -1.7% | - | - | - | 41.6% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -1218.8% | 0.0% | 0.0% | - | - | -45.1% | -42.9% | -12.1% | -29.0% | -56.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$20.16M totalReportable Segment$20.16M · 100.0%
Product / service
$20.16M totalDisposables$19.63M · 97.4%
Product And Service Other$528.0K · 2.6%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Acutus Medical against the 5 most active filers in the same SIC group.